Overview

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Status:
Terminated

Trial end date:
2017-08-07

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Methotrexate
Tumor Necrosis Factor Inhibitors